Incyte, a biotechnology company, agreed to acquire a minority stake in MorphoSys, a biotechnological research company, for $150m. "We are pleased to announce resolving the capital increase, which marks the final step in formalizing our partnership with Incyte. We are grateful for our partner's long-term commitment and are excited to kick off and operationalize our collaboration at full speed over the coming weeks and months," Jens Holstein, MorphoSys CFO.